DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Posaconazole and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[14] |
Ivosidenib |
DM8S6T7
|
Major |
Decreased metabolism of Posaconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[15] |
Midostaurin |
DMI6E0R
|
Major |
Decreased metabolism of Posaconazole caused by Midostaurin mediated inhibition of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[16] |
Arn-509 |
DMT81LZ
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Arn-509. |
Acute myeloid leukaemia [2A60]
|
[17] |
Gilteritinib |
DMTI0ZO
|
Major |
Decreased metabolism of Posaconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[18] |
Oliceridine |
DM6MDCF
|
Major |
Decreased metabolism of Posaconazole caused by Oliceridine mediated inhibition of CYP450 enzyme. |
Acute pain [MG31]
|
[19] |
Ivabradine |
DM0L594
|
Major |
Decreased metabolism of Posaconazole caused by Ivabradine mediated inhibition of CYP450 enzyme. |
Angina pectoris [BA40]
|
[14] |
Dronedarone |
DMA8FS5
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Dronedarone. |
Angina pectoris [BA40]
|
[20] |
Bedaquiline |
DM3906J
|
Major |
Decreased metabolism of Posaconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme. |
Antimicrobial drug resistance [MG50-MG52]
|
[21] |
Levalbuterol |
DM5YBO1
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Levalbuterol. |
Asthma [CA23]
|
[22] |
Pirbuterol |
DMI5678
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Pirbuterol. |
Asthma [CA23]
|
[23] |
Retigabine |
DMGNYIH
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Retigabine. |
Behcet disease [4A62]
|
[20] |
Cariprazine |
DMJYDVK
|
Major |
Decreased metabolism of Posaconazole caused by Cariprazine mediated inhibition of CYP450 enzyme. |
Bipolar disorder [6A60]
|
[24] |
Erdafitinib |
DMI782S
|
Major |
Decreased metabolism of Posaconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme. |
Bladder cancer [2C94]
|
[25] |
Pexidartinib |
DMS2J0Z
|
Major |
Decreased metabolism of Posaconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme. |
Bone/articular cartilage neoplasm [2F7B]
|
[26] |
Eribulin |
DM1DX4Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[20] |
Talazoparib |
DM1KS78
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[27] |
Ixabepilone |
DM2OZ3G
|
Moderate |
Decreased metabolism of Posaconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[28] |
HKI-272 |
DM6QOVN
|
Major |
Decreased metabolism of Posaconazole caused by HKI-272 mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[29] |
LY2835219 |
DM93VBZ
|
Major |
Decreased metabolism of Posaconazole caused by LY2835219 mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[30] |
Esterified estrogens |
DM9KZDO
|
Moderate |
Decreased metabolism of Posaconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[31] |
Tucatinib |
DMBESUA
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Tucatinib. |
Breast cancer [2C60-2C6Y]
|
[32] |
Palbociclib |
DMD7L94
|
Major |
Decreased metabolism of Posaconazole caused by Palbociclib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[33] |
Quinestrol |
DMJ6H1Z
|
Moderate |
Decreased metabolism of Posaconazole caused by Quinestrol mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[31] |
Cabazitaxel |
DMPAZHC
|
Moderate |
Decreased metabolism of Posaconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[14] |
Bosutinib |
DMTI8YE
|
Major |
Decreased metabolism of Posaconazole caused by Bosutinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[14] |
Trastuzumab Emtansine |
DMU1LXS
|
Moderate |
Decreased metabolism of Posaconazole caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[14] |
Macitentan |
DMP79A1
|
Major |
Decreased metabolism of Posaconazole caused by Macitentan mediated inhibition of CYP450 enzyme. |
Cardiovascular disease [BA00-BE2Z]
|
[34] |
PF-04449913 |
DMSB068
|
Major |
Decreased metabolism of Posaconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme. |
Chronic myelomonocytic leukaemia [2A40]
|
[35] |
Olodaterol |
DM62B78
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Posaconazole and Olodaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[23] |
Vilanterol |
DMF5EK1
|
Moderate |
Decreased metabolism of Posaconazole caused by Vilanterol mediated inhibition of CYP450 enzyme. |
Chronic obstructive pulmonary disease [CA22]
|
[36] |
Indacaterol |
DMQJHR7
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Posaconazole and Indacaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[23] |
Arformoterol |
DMYM974
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Arformoterol. |
Chronic obstructive pulmonary disease [CA22]
|
[23] |
Levomilnacipran |
DMV26S8
|
Major |
Decreased metabolism of Posaconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme. |
Chronic pain [MG30]
|
[37] |
Regorafenib |
DMHSY1I
|
Moderate |
Decreased metabolism of Posaconazole caused by Regorafenib mediated inhibition of CYP450 enzyme. |
Colorectal cancer [2B91]
|
[14] |
Intedanib |
DMSTA36
|
Moderate |
Decreased metabolism of Posaconazole caused by Intedanib mediated inhibition of CYP450 enzyme. |
Colorectal cancer [2B91]
|
[38] |
Drospirenone |
DM1A9W3
|
Major |
Decreased metabolism of Posaconazole caused by Drospirenone mediated inhibition of CYP450 enzyme. |
Contraceptive management [QA21]
|
[14] |
Levonorgestrel |
DM1DP7T
|
Moderate |
Decreased metabolism of Posaconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme. |
Contraceptive management [QA21]
|
[31] |
Ulipristal |
DMBNI20
|
Minor |
Decreased metabolism of Posaconazole caused by Ulipristal mediated inhibition of CYP450 enzyme. |
Contraceptive management [QA21]
|
[17] |
Probucol |
DMVZQ2M
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Probucol. |
Coronary atherosclerosis [BA80]
|
[20] |
Pasireotide |
DMHM7JS
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Pasireotide. |
Cushing syndrome [5A70]
|
[20] |
Osilodrostat |
DMIJC9X
|
Major |
Decreased metabolism of Posaconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[17] |
Ivacaftor |
DMZC1HS
|
Major |
Decreased metabolism of Posaconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[14] |
Rivaroxaban |
DMQMBZ1
|
Major |
Decreased metabolism of Posaconazole caused by Rivaroxaban mediated inhibition of CYP450 enzyme. |
Deep vein thrombosis [BD71]
|
[14] |
Vilazodone |
DM4LECQ
|
Major |
Decreased metabolism of Posaconazole caused by Vilazodone mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[39] |
OPC-34712 |
DMHG57U
|
Major |
Decreased metabolism of Posaconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[40] |
Polatuzumab vedotin |
DMF6Y0L
|
Major |
Decreased metabolism of Posaconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. |
Diffuse large B-cell lymphoma [2A81]
|
[41] |
[3H]estrone-3-sulphate |
DMGPF0N
|
Moderate |
Decreased metabolism of Posaconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. |
Discovery agent [N.A.]
|
[42] |
Tetrabenazine |
DMYWQ0O
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[20] |
Ospemifene |
DMC4GEI
|
Moderate |
Decreased metabolism of Posaconazole caused by Ospemifene mediated inhibition of CYP450 enzyme. |
Dyspareunia [GA12]
|
[43] |
Deutetrabenazine |
DMUPFLI
|
Moderate |
Additive CNS depression effects by the combination of Posaconazole and Deutetrabenazine. |
Dystonic disorder [8A02]
|
[44] |
Ingrezza |
DMVPLNC
|
Major |
Additive CNS depression effects by the combination of Posaconazole and Ingrezza. |
Dystonic disorder [8A02]
|
[45] |
Lacosamide |
DMVM6QR
|
Moderate |
Decreased metabolism of Posaconazole caused by Lacosamide mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[14] |
Cannabidiol |
DM0659E
|
Minor |
Decreased metabolism of Posaconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme. |
Epileptic encephalopathy [8A62]
|
[17] |
Bay 80-6946 |
DMLOS5R
|
Major |
Decreased clearance of Posaconazole due to the transporter inhibition by Bay 80-6946. |
Follicular lymphoma [2A80]
|
[46] |
Tazemetostat |
DMWP1BH
|
Major |
Decreased metabolism of Posaconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[47] |
Solifenacin |
DMG592Q
|
Major |
Decreased metabolism of Posaconazole caused by Solifenacin mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[14] |
Mirabegron |
DMS1GYT
|
Minor |
Decreased metabolism of Posaconazole caused by Mirabegron mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[48] |
Dexlansoprazole |
DM1DBV5
|
Moderate |
Decreased absorption of Posaconazole due to altered gastric pH caused by Dexlansoprazole. |
Gastro-oesophageal reflux disease [DA22]
|
[49] |
Ripretinib |
DM958QB
|
Major |
Decreased metabolism of Posaconazole caused by Ripretinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[14] |
Sunitinib |
DMCBJSR
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[20] |
Avapritinib |
DMK2GZX
|
Major |
Decreased metabolism of Posaconazole caused by Avapritinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[17] |
Colchicine |
DM2POTE
|
Major |
Decreased metabolism of Posaconazole caused by Colchicine mediated inhibition of CYP450 enzyme. |
Gout [FA25]
|
[50] |
Boceprevir |
DMBSHMF
|
Moderate |
Decreased metabolism of Posaconazole caused by Boceprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[51] |
ABT-450 |
DMFW860
|
Moderate |
Decreased metabolism of Posaconazole caused by ABT-450 mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[17] |
Simeprevir |
DMLUA9D
|
Major |
Decreased metabolism of Posaconazole caused by Simeprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[14] |
Telaprevir |
DMMRV29
|
Moderate |
Decreased metabolism of Posaconazole caused by Telaprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[51] |
Daclatasvir |
DMSFK9V
|
Major |
Decreased metabolism of Posaconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[17] |
GS-5885 |
DMSL3DX
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by GS-5885. |
Hepatitis virus infection [1E50-1E51]
|
[52] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[53] |
MK-1439 |
DM215WE
|
Minor |
Decreased metabolism of Posaconazole caused by MK-1439 mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[54] |
Fostemsavir |
DM50ILT
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Fostemsavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[55] |
Cobicistat |
DM6L4H2
|
Moderate |
Decreased metabolism of Posaconazole caused by Cobicistat mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[56] |
Dolutegravir |
DMCZGRE
|
Minor |
Decreased metabolism of Posaconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[57] |
Etravirine |
DMGV8QU
|
Moderate |
Decreased metabolism of Posaconazole caused by Etravirine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[58] |
Lopinavir |
DMITQS0
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Lopinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[20] |
Rilpivirine |
DMJ0QOW
|
Moderate |
Decreased metabolism of Posaconazole caused by Rilpivirine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[59] |
Maraviroc |
DMTL94F
|
Major |
Decreased metabolism of Posaconazole caused by Maraviroc mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[60] |
Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Posaconazole and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[61] |
Teriflunomide |
DMQ2FKJ
|
Major |
Increased risk of hepatotoxicity by the combination of Posaconazole and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[20] |
BMS-201038 |
DMQTAGO
|
Major |
Decreased metabolism of Posaconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[14] |
Sodium zirconium cyclosilicate |
DMCSLZ4
|
Moderate |
Decreased absorption of Posaconazole due to altered gastric pH caused by Sodium zirconium cyclosilicate. |
Hyperkalaemia [5C76]
|
[17] |
Aliskiren |
DM1BV7W
|
Moderate |
Decreased metabolism of Posaconazole caused by Aliskiren mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[20] |
Levamlodipine |
DM92S6N
|
Moderate |
Decreased metabolism of Posaconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[62] |
Tolvaptan |
DMIWFRL
|
Major |
Decreased metabolism of Posaconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme. |
Hypo-osmolality/hyponatraemia [5C72]
|
[14] |
TP-434 |
DM5A31S
|
Minor |
Decreased metabolism of Posaconazole caused by TP-434 mediated inhibition of CYP450 enzyme. |
Infectious gastroenteritis/colitis [1A40]
|
[63] |
Berotralstat |
DMWA2DZ
|
Major |
Decreased clearance of Posaconazole due to the transporter inhibition by Berotralstat. |
Innate/adaptive immunodeficiency [4A00]
|
[64] |
Suvorexant |
DM0E6S3
|
Major |
Decreased metabolism of Posaconazole caused by Suvorexant mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[14] |
Tasimelteon |
DMLOQ1V
|
Moderate |
Decreased metabolism of Posaconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[65] |
ITI-007 |
DMUQ1DO
|
Major |
Decreased metabolism of Posaconazole caused by ITI-007 mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[66] |
Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Posaconazole and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[17] |
Phenolphthalein |
DM5SICT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Posaconazole and Phenolphthalein. |
Irritable bowel syndrome [DD91]
|
[20] |
Eluxadoline |
DMYZ0P1
|
Moderate |
Decreased metabolism of Posaconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme. |
Irritable bowel syndrome [DD91]
|
[67] |
Naloxegol |
DML0B41
|
Major |
Decreased metabolism of Posaconazole caused by Naloxegol mediated inhibition of CYP450 enzyme. |
Large intestine motility disorder [DB32]
|
[14] |
Crizotinib |
DM4F29C
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Crizotinib. |
Lung cancer [2C25]
|
[68] |
Brigatinib |
DM7W94S
|
Major |
Decreased metabolism of Posaconazole caused by Brigatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[69] |
Ceritinib |
DMB920Z
|
Major |
Decreased metabolism of Posaconazole caused by Ceritinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[14] |
Lurbinectedin |
DMEFRTZ
|
Major |
Decreased metabolism of Posaconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[70] |
PF-06463922 |
DMKM7EW
|
Major |
Decreased metabolism of Posaconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[71] |
Osimertinib |
DMRJLAT
|
Major |
Decreased metabolism of Posaconazole caused by Osimertinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[72] |
Pralsetinib |
DMWU0I2
|
Major |
Decreased metabolism of Posaconazole caused by Pralsetinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[73] |
Capmatinib |
DMYCXKL
|
Major |
Decreased metabolism of Posaconazole caused by Capmatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[74] |
Selpercatinib |
DMZR15V
|
Major |
Decreased metabolism of Posaconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[17] |
Artemether |
DM48QOT
|
Major |
Decreased metabolism of Posaconazole caused by Artemether mediated inhibition of CYP450 enzyme. |
Malaria [1F40-1F45]
|
[14] |
Hydroxychloroquine |
DMSIVND
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Hydroxychloroquine. |
Malaria [1F40-1F45]
|
[75] |
Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[17] |
Calaspargase pegol |
DMQZBXI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Posaconazole and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[76] |
Idelalisib |
DM602WT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Posaconazole and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[77] |
GDC-0199 |
DMH0QKA
|
Major |
Decreased metabolism of Posaconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[78] |
IPI-145 |
DMWA24P
|
Major |
Decreased metabolism of Posaconazole caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[79] |
Acalabrutinib |
DM7GCVW
|
Major |
Decreased metabolism of Posaconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[80] |
Ibrutinib |
DMHZCPO
|
Major |
Decreased metabolism of Posaconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[14] |
Ponatinib |
DMYGJQO
|
Major |
Decreased metabolism of Posaconazole caused by Ponatinib mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[14] |
Arry-162 |
DM1P6FR
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Arry-162. |
Melanoma [2C30]
|
[14] |
Vemurafenib |
DM62UG5
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Vemurafenib. |
Melanoma [2C30]
|
[20] |
Selumetinib |
DMC7W6R
|
Major |
Decreased metabolism of Posaconazole caused by Selumetinib mediated inhibition of CYP450 enzyme. |
Melanoma [2C30]
|
[81] |
LGX818 |
DMNQXV8
|
Major |
Decreased metabolism of Posaconazole caused by LGX818 mediated inhibition of CYP450 enzyme. |
Melanoma [2C30]
|
[82] |
Dabrafenib |
DMX6OE3
|
Moderate |
Decreased metabolism of Posaconazole caused by Dabrafenib mediated inhibition of CYP450 enzyme. |
Melanoma [2C30]
|
[14] |
Ubrogepant |
DM749I3
|
Major |
Decreased metabolism of Posaconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[83] |
Rimegepant |
DMHOAUG
|
Moderate |
Decreased metabolism of Posaconazole caused by Rimegepant mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[84] |
Lasmiditan |
DMXLVDT
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Lasmiditan. |
Migraine [8A80]
|
[85] |
Flibanserin |
DM70DTN
|
Major |
Decreased metabolism of Posaconazole caused by Flibanserin mediated inhibition of CYP450 enzyme. |
Mood disorder [6A60-6E23]
|
[86] |
Siponimod |
DM2R86O
|
Major |
Increased risk of ventricular arrhythmias by the combination of Posaconazole and Siponimod. |
Multiple sclerosis [8A40]
|
[14] |
Fingolimod |
DM5JVAN
|
Major |
Increased risk of ventricular arrhythmias by the combination of Posaconazole and Fingolimod. |
Multiple sclerosis [8A40]
|
[20] |
Ozanimod |
DMT6AM2
|
Major |
Increased risk of ventricular arrhythmias by the combination of Posaconazole and Ozanimod. |
Multiple sclerosis [8A40]
|
[87] |
Deflazacort |
DMV0RNS
|
Major |
Decreased metabolism of Posaconazole caused by Deflazacort mediated inhibition of CYP450 enzyme. |
Muscular dystrophy [8C70]
|
[17] |
Romidepsin |
DMT5GNL
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Romidepsin. |
Mycosis fungoides [2B01]
|
[20] |
Fedratinib |
DM4ZBK6
|
Major |
Decreased metabolism of Posaconazole caused by Fedratinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[17] |
Nilotinib |
DM7HXWT
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Nilotinib. |
Myeloproliferative neoplasm [2A20]
|
[20] |
Ruxolitinib |
DM7Q98D
|
Major |
Decreased metabolism of Posaconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[88] |
Vorapaxar |
DMA16BR
|
Major |
Decreased metabolism of Posaconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme. |
Myocardial infarction [BA41-BA43]
|
[14] |
Rolapitant |
DM8XP26
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Rolapitant. |
Nausea/vomiting [MD90]
|
[89] |
E-2007 |
DMJDYNQ
|
Minor |
Decreased metabolism of Posaconazole caused by E-2007 mediated inhibition of CYP450 enzyme. |
Neuropathy [8C0Z]
|
[17] |
Entrectinib |
DMMPTLH
|
Major |
Decreased metabolism of Posaconazole caused by Entrectinib mediated inhibition of CYP450 enzyme. |
Non-small cell lung cancer [2C25]
|
[14] |
Lofexidine |
DM1WXA6
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Lofexidine. |
Opioid use disorder [6C43]
|
[20] |
S-297995 |
DM26IH8
|
Moderate |
Decreased metabolism of Posaconazole caused by S-297995 mediated inhibition of CYP450 enzyme. |
Opioid use disorder [6C43]
|
[17] |
Olaparib |
DM8QB1D
|
Major |
Decreased metabolism of Posaconazole caused by Olaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[14] |
Rucaparib |
DM9PVX8
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Rucaparib. |
Ovarian cancer [2C73]
|
[20] |
Triclabendazole |
DMPWGBR
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[20] |
Istradefylline |
DM20VSK
|
Major |
Decreased metabolism of Posaconazole caused by Istradefylline mediated inhibition of CYP450 enzyme. |
Parkinsonism [8A00]
|
[90] |
Pimavanserin |
DMR7IVC
|
Major |
Decreased metabolism of Posaconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme. |
Parkinsonism [8A00]
|
[91] |
Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[92] |
Lefamulin |
DME6G97
|
Major |
Decreased metabolism of Posaconazole caused by Lefamulin mediated inhibition of CYP450 enzyme. |
Pneumonia [CA40]
|
[93] |
Lonafarnib |
DMGM2Z6
|
Major |
Decreased metabolism of Posaconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. |
Premature ageing appearance [LD2B]
|
[94] |
Degarelix |
DM3O8QY
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Degarelix. |
Prostate cancer [2C82]
|
[17] |
Enzalutamide |
DMGL19D
|
Moderate |
Decreased metabolism of Posaconazole caused by Enzalutamide mediated inhibition of CYP450 enzyme. |
Prostate cancer [2C82]
|
[95] |
Relugolix |
DMK7IWL
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Relugolix. |
Prostate cancer [2C82]
|
[17] |
Darolutamide |
DMV7YFT
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Darolutamide. |
Prostate cancer [2C82]
|
[96] |
Silodosin |
DMJSBT6
|
Major |
Decreased metabolism of Posaconazole caused by Silodosin mediated inhibition of CYP450 enzyme. |
Prostate hyperplasia [GA90]
|
[14] |
Levomepromazine |
DMIKFEL
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[20] |
Ambrisentan |
DMD1QXW
|
Minor |
Decreased metabolism of Posaconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme. |
Pulmonary hypertension [BB01]
|
[97] |
Riociguat |
DMXBLMP
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Riociguat. |
Pulmonary hypertension [BB01]
|
[14] |
Everolimus |
DM8X2EH
|
Major |
Decreased metabolism of Posaconazole caused by Everolimus mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[14] |
Axitinib |
DMGVH6N
|
Major |
Decreased metabolism of Posaconazole caused by Axitinib mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[14] |
Temsirolimus |
DMS104F
|
Major |
Increased metabolism of Posaconazole caused by Temsirolimus mediated induction of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[14] |
Ciclesonide |
DM2NA4K
|
Moderate |
Decreased metabolism of Posaconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme. |
Respiratory system disease [CB40-CB7Z]
|
[98] |
Upadacitinib |
DM32B5U
|
Major |
Decreased metabolism of Posaconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[99] |
Tofacitinib |
DMBS370
|
Major |
Decreased metabolism of Posaconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[14] |
Iloperidone |
DM6AUFY
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Iloperidone. |
Schizophrenia [6A20]
|
[20] |
Paliperidone |
DM7NPJS
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Paliperidone. |
Schizophrenia [6A20]
|
[20] |
Amisulpride |
DMSJVAM
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Amisulpride. |
Schizophrenia [6A20]
|
[14] |
Asenapine |
DMSQZE2
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Asenapine. |
Schizophrenia [6A20]
|
[20] |
Avanafil |
DM75CXN
|
Major |
Decreased metabolism of Posaconazole caused by Avanafil mediated inhibition of CYP450 enzyme. |
Sexual dysfunction [HA00-HA01]
|
[14] |
Voxelotor |
DMCS6M5
|
Major |
Decreased metabolism of Posaconazole caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[100] |
LDE225 |
DMM9F25
|
Major |
Decreased metabolism of Posaconazole caused by LDE225 mediated inhibition of CYP450 enzyme. |
Skin cancer [2C30-2C37]
|
[101] |
Larotrectinib |
DM26CQR
|
Major |
Decreased metabolism of Posaconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[14] |
Trabectedin |
DMG3Y89
|
Major |
Decreased metabolism of Posaconazole caused by Trabectedin mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[14] |
Armodafinil |
DMGB035
|
Minor |
Decreased metabolism of Posaconazole caused by Armodafinil mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[14] |
LEE011 |
DMMX75K
|
Major |
Decreased metabolism of Posaconazole caused by LEE011 mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[102] |
Vandetanib |
DMRICNP
|
Major |
Increased risk of prolong QT interval by the combination of Posaconazole and Vandetanib. |
Solid tumour/cancer [2A00-2F9Z]
|
[20] |
Triptorelin |
DMTK4LS
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Triptorelin. |
Solid tumour/cancer [2A00-2F9Z]
|
[17] |
Pitolisant |
DM8RFNJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Pitolisant. |
Somnolence [MG42]
|
[20] |
Telavancin |
DM58VQX
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[20] |
Pomalidomide |
DMTGBAX
|
Moderate |
Decreased metabolism of Posaconazole caused by Pomalidomide mediated inhibition of CYP450 enzyme. |
Systemic sclerosis [4A42]
|
[14] |
Fostamatinib |
DM6AUHV
|
Major |
Decreased metabolism of Posaconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[103] |
Lusutrombopag |
DMH6IKO
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Lusutrombopag. |
Thrombocytopenia [3B64]
|
[104] |
As-1670542 |
DMV05SW
|
Moderate |
Decreased metabolism of Posaconazole caused by As-1670542 mediated inhibition of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[17] |
Apixaban |
DM89JLN
|
Major |
Decreased clearance of Posaconazole due to the transporter inhibition by Apixaban. |
Thrombosis [DB61-GB90]
|
[14] |
Brilinta |
DMBR01X
|
Major |
Decreased metabolism of Posaconazole caused by Brilinta mediated inhibition of CYP450 enzyme. |
Thrombosis [DB61-GB90]
|
[14] |
Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of prolong QT interval by the combination of Posaconazole and Lenvatinib. |
Thyroid cancer [2D10]
|
[20] |
Cabozantinib |
DMIYDT4
|
Major |
Decreased metabolism of Posaconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme. |
Thyroid cancer [2D10]
|
[14] |
Saxagliptin |
DMGXENV
|
Moderate |
Decreased metabolism of Posaconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme. |
Type 2 diabetes mellitus [5A11]
|
[17] |
Elagolix |
DMB2C0E
|
Major |
Decreased metabolism of Posaconazole caused by Elagolix mediated inhibition of CYP450 enzyme. |
Uterine fibroid [2E86]
|
[105] |
Fluticasone |
DMGCSVF
|
Major |
Decreased metabolism of Posaconazole caused by Fluticasone mediated inhibition of CYP450 enzyme. |
Vasomotor/allergic rhinitis [CA08]
|
[106] |
Betrixaban |
DM2C4RF
|
Moderate |
Decreased clearance of Posaconazole due to the transporter inhibition by Betrixaban. |
Venous thromboembolism [BD72]
|
[107] |
----------- |
|
|
|
|
|